title: Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass.
abstract: The biocompatibility of the cardiopulmonary bypass (CPB) circuit, in which an oxygenator is solely heparinized, was assessed by systemic inflammatory reactions as an indicator during CPB. Fourteen patients, 11 males and 3 females, underwent coronary artery bypass surgery and were randomly divided into 2 groups of 7 patients each. For the heparin-coated oxygenator group (Group H), a heparin-coated membrane oxygenator was used in the CPB circuit, and in the control (Group C) an uncoated membrane oxygenator was employed. Systemic inflammatory reactions, such as platelet activation, prostaglandin production, complement activation, and activated granulocyte released substance, were measured prior to, during, and 6 h after CPB. The number of platelets decreased after protamine administration in both groups (14.5 +/- 4.7 x 10(4)/microliters in Group H and 13.8 +/- 8.7 x 10(4)/microliters in Group C) and returned to baseline levels in Group H while it remained decreased in Group C at 6 h after CPB. The platelet factor 4 level was significantly lower in Group H (181 +/- 40 ng/ml) than in Group C (297 +/- 131 ng/ml) after protamine administration. Thromboxane-B2 (TXB2) rose during CPB in both groups; however, there were significantly different levels of TXB2 between the 2 groups at 60 min after CPB (293 +/- 258 pg/ml in Group H versus 408 +/- 120 pg/ml in Group C) and after protamine administration (259 +/- 122 pg/ml in Group H versus 709 +/- 418 pg/ml in Group C). Plasma concentrations of granulocyte elastase were significantly lower in Group H at 30, 60 and 90 min, immediately after, and post-CPB than those of Group C.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery II, National Defense Medical College, Saitama, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Hatori
authors.forename: H
authors.initials: H
authors.lastname: Yoshizu
authors.forename: Y
authors.initials: Y
authors.lastname: Haga
authors.forename: Y
authors.initials: Y
authors.lastname: Kusama
authors.forename: S
authors.initials: S
authors.lastname: Takeshima
authors.forename: D
authors.initials: D
authors.lastname: Segawa
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D001672:Biocompatible Materials / Q000737:chemistry; D002315:Cardiopulmonary Bypass / Q000295:instrumentation*; D003167:Complement Activation; D001026:Coronary Artery Bypass; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006493:Heparin; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D019272:Leukocyte Elastase; D008297:Male; D008875:Middle Aged; D010107:Oxygenators, Membrane; D010196:Pancreatic Elastase / Q000097:blood; D015539:Platelet Activation; D010976:Platelet Count / Q000187:drug effects; D010978:Platelet Factor 4 / Q000032:analysis; D011479:Protamines / Q000627:therapeutic use; D013499:Surface Properties; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D001672:Biocompatible Materials; D006454:Hemoglobins; D011479:Protamines; D010978:Platelet Factor 4; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D006493:Heparin; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase